$1.14
0.87%
Nasdaq, Oct 21, 04:00 pm EDT. Closed.
ISIN
US83558L1052
Symbol
SNOA

Sonoma Pharmaceuticals, Inc. Stock price

$1.14
-0.11 8.80% 1M
-1.11 49.33% 6M
-2.50 68.68% YTD
-2.75 70.69% 1Y
-9.18 88.96% 3Y
-112.86 99.00% 5Y
-718.86 99.84% 10Y
-49,138.86 100.00% 20Y
Nasdaq, Closing price Wed, Oct 21 2026
-0.01 0.87%
ISIN
US83558L1052
Symbol
SNOA
Industry

Is Sonoma Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
$5.5m
Enterprise Value
$310.0k
Net debt
positive
Cash
$5.3m
Shares outstanding
4.8m
Valuation
P/E
negative
P/S | estimate
0.3 | 0.3
EV/Sales | estimate
0.0 | 0.0
EV/FCF | ex SBC
negative | negative
P/B
0.8
Financial Health
Equity Ratio
22.2%
Return on Equity
-102.6%
ROCE
-11.1%
ROIC
-12.3%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$260.0k | 1.2%
SBC as % of FCF
-
SBC Growth 1Y
52.9%
Share Count Growth 1Y
192.1%
Shareholder Yield
-192.1%
Financials
Revenue | estimate
$21.9m | $21.9m
EBITDA
$-1.3m
EBIT
$-1.4m
Net Income
$-2.3m
Free Cash Flow | ex SBC
$-2.6m | $-2.9m
Growth
Revenue | estimate
47.0% | 12.1%
EBITDA
63.7%
EBIT
61.3%
Net Income
36.5%
Free Cash Flow
-92.7%
Margin
Gross
38.9%
EBITDA
-5.8%
EBIT
-6.4%
Net
-10.3%
Free Cash Flow | ex SBC
-12.0% | -13.2%
More
EPS
$-0.6
FCF per Share
$-0.6
Short interest
3.5%
Employees
8
Rev per Employee
$2.4m

Sonoma Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast:

Buy
86%
Hold
14%

Sonoma Pharmaceuticals, Inc. Events

Upcoming Event
NOV
2
Q2 2027 Earnings Call
in 12 days
View Past Earnings Reaction

Financial data from Sonoma Pharmaceuticals, Inc.

Jun '26
+/-
%
22 22
47% 47%
100%
- Direct Costs 13 13
44% 44%
61%
8.53 8.53
52% 52%
39%
- Selling and Administrative Expenses 7.66 7.66
5% 5%
35%
- Research and Development Expense 2.27 2.27
17% 17%
10%
-1.27 -1.27
64% 64%
-6%
- Depreciation and Amortization 0.14 0.14
0% 0%
1%
EBIT (Operating Income) EBIT -1.41 -1.41
61% 61%
-6%
Net Profit -2.26 -2.26
37% 37%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about Sonoma Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sonoma Pharmaceuticals, Inc. Stock News

Neutral
Accesswire
●
3 months ago
Total revenue increased 60% year over year to $6.4 million Net loss per share decreased 88% compared to the prior-year quarter Gross margin expanded to 40% as operating expenses remained stable FDA clearance and new global distributors support continued commercial growth BOULDER, CO / ACCESS Newswire / August 6, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader devel...
Neutral
Accesswire
●
4 months ago
BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microdacyn® Wound Irrigation Solution, including expanded claims, clearance for multiple use, and additional packaging configu...
Neutral
Accesswire
●
4 months ago
Revenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025 United States revenues increased 194% in Q4 2026 compared to Q4 2025 and 117% in FY 2026 compared to FY 2025 Net loss improved 25% in Q4 2026 compared to Q4 2025, and 8% in FY 2026 compared to FY 2025 EBITDA loss improved 66% in Q4 2026 compared to Q4 2025, and 38% in FY 2026 compared to FY 2025 BOULDE...
More Sonoma Pharmaceuticals, Inc. News

Company Profile

Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. The company offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Petaluma, CA.

Head office United States
CEO Ms. Trombly
Employees 8
Founded 1999
Website sonomapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today